|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||17.40 - 18.30|
|52 Week Range||11.88 - 29.09|
|Beta (5Y Monthly)||0.05|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Celebrations may be in order for AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders, with the analysts delivering a...
AnaptysBio Inc’s (NASDAQ: ANAB) stock seems attractive after the POPLAR data and the 30% selloff, while there are several catalysts over the next 12-18 months, according to Truist Securities. AnaptysBio is a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients, according to its website. The AnaptysBio Analyst: Joon Lee upgraded the rating for AnaptysBio from Hold to Buy, while raising the price target from $27 to $34. The AnaptysBio Thesis: The company is posed for value creation in 2021 and 2022, given the “rich pipeline from wholly-owned and partnered programs,” Lee said in the upgrade note. “Our due diligence suggest imsidolimab may have stronger rationale for EGFRi mediated skin toxicity with interim topline expected YE21. And GPP, for which ANAB is planning to start Ph3 mid-2021, may be a much larger indication than we currently model,” he wrote. “Also, we like the rich pipeline, including ANB030, a PD-1 agonist (LLY also has one) and ANB032, a BLTA modulator. Lastly, we raise ANAB floor based on updated milestone expectations from GSK collab,” the analyst said. ANAB Price Action: Shares of AnaptysBio had risen by 2.95% to $20.40 at the time of publication Tuesday. (Photo by Bill Oxford on Unsplash) Latest Ratings for ANAB DateFirmActionFromTo Mar 2021Truist SecuritiesUpgradesHoldBuy Mar 2021WedbushDowngradesOutperformNeutral Feb 2021JP MorganUpgradesUnderweightOverweight View More Analyst Ratings for ANAB View the Latest Analyst Ratings See more from BenzingaClick here for options trades from BenzingaWhy Advanced Micro Devices's EPYC3 Server Launch Impressed This AnalystHere's Why BofA Raised US Steel Target By 50%© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Shares of clinical-stage biotech AnaptysBio (NASDAQ: ANAB) were rising sharply on Tuesday following bullish commentary from a Wall Street analyst. The company's stock was up by 5.6% as of 12:58 p.m. EDT, after rising by as much as 12% earlier in the day. Truist analyst Joon Lee upgraded AnaptysBio stock to buy from hold.